Disclosure of interest: None Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P621 - ESOC25-1482 STRATEGY FOR IMPROVING STROKE TREATMENT RESPONSE (SISTER): A PHASE-2 CLINICAL TRIAL OF TS23, A NOVEL MECHANISM FOR IMPROVING OUTCOMES IN ACUTE ISCHEMIC STROKE Eva Mistry 1 , Jordan Elm 2 , Pamela Plummer 1 , Rebeca Aragon Garcia 1 , Paul Kussie 3 , Ryan Sullivan 3 , Iris Davis 1 , Yasmin Aziz 1 , Vivek Khandwala 1 , Achala Vagal 1 , Noor Sabagha 1 , Joseph Broderick 1 , Guy Reed 3 , Pooja Khatri 1 , Scott Janis 4 1 University of Cincinnati, Cincinnati, United States, 2 Medical University of South Carolina, Charleston, United States, 3 Translational Sciences, Inc., Phoenix, United States, 4 National Institute of Neurological Disorder and Stroke, Bethesda, United States Background and Aims: Plasminogen activators for acute ischemic stroke (AIS) suffer from limitations of a narrow therapeutic window, suboptimal thrombolysis of larger clots, paradoxical microthrombosis, neurotoxic effects and hemorrhage
People talk about it for tissue repair and gut wellness
For higher body weights, this scale can be extended even further
Each batch is produced under controlled conditions and verified for consistency and purity to support reliable laboratory research
